Search

everythinglearnresearchcommunity

for

Search:↓

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Certain KIR genes in Indian SLE patients are linked to disease severity and could be biomarkers.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Diagnosing new systemic lupus during pregnancy is hard but important for the health of the mother and baby.

Fibromyalgia slightly more common in SLE patients but doesn't affect SLE activity assessments.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.

Early detection and targeted management are crucial for better outcomes in systemic lupus erythematosus.

Patients with lupus nephritis and COVID-19 can improve with proper treatment.

Hydroxychloroquine may help COVID-19 patients with lupus.

Adding colchicine stopped the girl's recurring heart issues caused by lupus.

Patients with Discoid Lupus Erythematosus have lower vitamin D and antioxidant levels and higher oxidative stress.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

Lupus can cause different skin problems, and treatments like quitting smoking and using certain creams or medicines can help.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

An imbalance in gut bacteria is linked to skin immune diseases and may affect their outcomes and related health issues.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Hair loss can indicate or worsen with systemic diseases, and treating the underlying condition is important.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Early detection and infection prevention are crucial for improving survival in pediatric lupus patients with aplastic anemia.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.